Pharmacogenomics: unlocking the human genome for better drug therapy
- PMID: 11264452
- DOI: 10.1146/annurev.pharmtox.41.1.101
Pharmacogenomics: unlocking the human genome for better drug therapy
Abstract
There is great heterogeneity in the way humans respond to medications, often requiring empirical strategies to find the appropriate drug therapy for each patient (the "art" of medicine). Over the past 50 years, there has been great progress in understanding the molecular basis of drug action and in elucidating genetic determinants of disease pathogenesis and drug response. Pharmacogenomics is the burgeoning field of investigation that aims to further elucidate the inherited nature of interindividual differences in drug disposition and effects, with the ultimate goal of providing a stronger scientific basis for selecting the optimal drug therapy and dosages for each patient. These genetic insights should also lead to mechanism-based approaches to the discovery and development of new medications. This review highlights the current status of work in this field and addresses strategies that hold promise for future advances in pharmacogenomics.
Similar articles
-
Cancer pharmacogenomics: SNPs, chips, and the individual patient.Cancer Invest. 2003;21(4):630-40. doi: 10.1081/cnv-120022384. Cancer Invest. 2003. PMID: 14533451 Review.
-
Pharmacogenomics: the inherited basis for interindividual differences in drug response.Annu Rev Genomics Hum Genet. 2001;2:9-39. doi: 10.1146/annurev.genom.2.1.9. Annu Rev Genomics Hum Genet. 2001. PMID: 11701642 Review.
-
Pharmacogenomics: translating functional genomics into rational therapeutics.Science. 1999 Oct 15;286(5439):487-91. doi: 10.1126/science.286.5439.487. Science. 1999. PMID: 10521338 Review.
-
Pharmacogenomics: marshalling the human genome to individualise drug therapy.Gut. 2003 May;52 Suppl 2(Suppl 2):ii10-8. doi: 10.1136/gut.52.suppl_2.ii10. Gut. 2003. PMID: 12651877 Free PMC article. Review.
-
[Pharmacogenomics genomics approaches to optimizing drug therapy].Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2002 Apr;19(2):156-8. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2002. PMID: 11941596 Review. Chinese.
Cited by
-
Future prospects of personalized chemotherapy in gastric cancer patients: results of a prospective randomized pilot study.Gastric Cancer. 2003;6 Suppl 1:82-9. doi: 10.1007/s10120-003-0224-9. Gastric Cancer. 2003. PMID: 12775025 Clinical Trial.
-
XPD DNA nucleotide excision repair gene polymorphisms associated with DNA repair deficiency predict better treatment outcomes in secondary acute myeloid leukemia.Int J Mol Epidemiol Genet. 2010;1(4):278-94. Epub 2010 Aug 10. Int J Mol Epidemiol Genet. 2010. PMID: 21394217 Free PMC article.
-
UGT1A1, UGT1A6 and UGT1A7 genetic analysis: repercussion for irinotecan pharmacogenetics in the São Miguel Island Population (Azores, Portugal).Mol Diagn Ther. 2009;13(4):261-8. doi: 10.2165/11317170-000000000-00000. Mol Diagn Ther. 2009. PMID: 19712005
-
Pharmacogenetics: implications for therapy in rheumatic diseases.Nat Rev Rheumatol. 2011 Aug 9;7(9):537-50. doi: 10.1038/nrrheum.2011.117. Nat Rev Rheumatol. 2011. PMID: 21826093 Review.
-
Genetic polymorphisms of adrenergic receptors.Clin Auton Res. 2001 Apr;11(2):67-78. doi: 10.1007/BF02322049. Clin Auton Res. 2001. PMID: 11570606 Review.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous